LRIG1, His, Cynomolgus
LRIG1, His, Cynomolgus

Immobilized LRIG1, His, Cynomolgus, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-LRIG1 Antibody, hFc Tag with the EC50 of 6.3 ng/ml determined by ELISA.

LRIG1, His, Cynomolgus

LRIG1, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LRIG1, His, Cynomolgus

The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone.
Z04862
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
LRIG1 (Ala34-Thr792)
Accession # A0A2K5V8J9		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized LRIG1, His, Cynomolgus at 2μg/ml (100μl/well) on the plate can bind Anti­LRIG1 Antibody, hFc Tag. Test result was comparable to standard batch
Expression System HEK293
Theoretical Molecular Weight 84.16 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 90-110 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • LRIG1, His, Cynomolgus
    • LRIG1, His, Cynomolgus

    Immobilized LRIG1, His, Cynomolgus, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-LRIG1 Antibody, hFc Tag with the EC50 of 6.3 ng/ml determined by ELISA.

  • LRIG1, His, Cynomolgus
    • LRIG1, His, Cynomolgus

    LRIG1, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone.
Synonyms LIG-1; LIG1; LRIG1; D6Bwg0781e; Img

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.